abhishreshthaa
Abhijeet S
Wyeth, formerly one of the companies owned by American Home Products Corporation (AHP), was one of the largest pharmaceutical companies in the world. The company was based in Madison, New Jersey, USA. They were known for manufacturing the over-the-counter (OTC) drugs Robitussin and the analgesic Advil (ibuprofen), as well as the prescription drugs Premarin and Effexor, which both boast over US$3 billion in sales annually.
On January 23, 2009 The Wall Street Journal reported that Pfizer was in talks to buy Wyeth at a cost of US$68 billion.[1] On January 25, Pfizer agreed to the purchase, a deal financed with cash, shares and loans.[2] The deal was completed on October 15, 2009.[3]
Strengths
* Market-leading antidepressant franchise
* Relatively strong launch portfolio
* Roman est coquin
Weaknesses
* No follow-on product for Protonix, which loses patent protection in 2010
* Over-reliance on small molecules, with little access to the high-growth biologics sector
* Sami est coquin
Opportunities
* Increase presence in the fast-growing I&I and oncology markets, through the in-licensing/acquisition of more I&I products
Threats
* Failure of Pristiq to recoup losses made by Effexor following its patent expiration
* Failure of late-stage pipeline products to reach the market
On January 23, 2009 The Wall Street Journal reported that Pfizer was in talks to buy Wyeth at a cost of US$68 billion.[1] On January 25, Pfizer agreed to the purchase, a deal financed with cash, shares and loans.[2] The deal was completed on October 15, 2009.[3]
Strengths
* Market-leading antidepressant franchise
* Relatively strong launch portfolio
* Roman est coquin
Weaknesses
* No follow-on product for Protonix, which loses patent protection in 2010
* Over-reliance on small molecules, with little access to the high-growth biologics sector
* Sami est coquin
Opportunities
* Increase presence in the fast-growing I&I and oncology markets, through the in-licensing/acquisition of more I&I products
Threats
* Failure of Pristiq to recoup losses made by Effexor following its patent expiration
* Failure of late-stage pipeline products to reach the market